FORTRESS BIOTECH INC (FBIO) Stock Price, Forecast & Analysis
USA - NASDAQ:FBIO - US34960Q3074 - Common Stock
FBIO Key Statistics, Chart & Performance
The current stock price of FBIO is 2.68 USD. In the past month the price decreased by -1.83%. In the past year, price increased by 87.41%.
FBIO Latest News, Press Relases and Analysis
FBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.83 | 397.78B | ||
| AMGN | AMGEN INC | 15.48 | 182.21B | ||
| GILD | GILEAD SCIENCES INC | 14.96 | 152.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.72 | 110.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.99 | 71.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 886.18 | 59.24B | ||
| INSM | INSMED INC | N/A | 40.94B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 9.53 | 23.39B | ||
| INCY | INCYTE CORP | 16.85 | 21.12B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.4 | 20.77B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.24 | 14.61B |
Related stock screener links
About FBIO
Company Profile
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Company Info
FORTRESS BIOTECH INC
1111 Kane Concourse, Suite 301
Bay Harbor Islands FLORIDA 10014 US
CEO: Lindsay A. Rosenwald
Employees: 101
Phone: 17816524500
FORTRESS BIOTECH INC / FBIO FAQ
What does FBIO do?
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
What is the current price of FBIO stock?
The current stock price of FBIO is 2.68 USD. The price increased by 3.47% in the last trading session.
What is the dividend status of FORTRESS BIOTECH INC?
FBIO does not pay a dividend.
What is the ChartMill rating of FORTRESS BIOTECH INC stock?
FBIO has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting FBIO stock to perform?
8 analysts have analysed FBIO and the average price target is 10.71 USD. This implies a price increase of 299.63% is expected in the next year compared to the current price of 2.68.
Who owns FORTRESS BIOTECH INC?
You can find the ownership structure of FORTRESS BIOTECH INC (FBIO) on the Ownership tab.
What is the outstanding short interest for FORTRESS BIOTECH INC?
The outstanding short interest for FORTRESS BIOTECH INC (FBIO) is 14.37% of its float.
FBIO Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to FBIO. When comparing the yearly performance of all stocks, FBIO is one of the better performing stocks in the market, outperforming 93.25% of all stocks.
FBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FBIO. FBIO has a bad profitability rating. Also its financial health evaluation is rather negative.
FBIO Financial Highlights
Over the last trailing twelve months FBIO reported a non-GAAP Earnings per Share(EPS) of -2.49. The EPS increased by 37.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.04% | ||
| ROE | -54.76% | ||
| Debt/Equity | 1.14 |
FBIO Forecast & Estimates
8 analysts have analysed FBIO and the average price target is 10.71 USD. This implies a price increase of 299.63% is expected in the next year compared to the current price of 2.68.
For the next year, analysts expect an EPS growth of 69.12% and a revenue growth 26.68% for FBIO